Fundraising Fox
Splisense
Founded 2017 · 16 employees on LinkedIn · 1 known investors
Find your way into Splisense
Sign up to see every warm intro you have to Splisense
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Splisense team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SpliSense develops antisense oligonucleotides (ASOs) — small synthetic RNA-binding molecules — designed using proprietary algorithms for therapeutic applications including splicing modulation and gene silencing. The company focuses on inhaled ASOs delivered directly to the lungs for treating pulmonary and obstructive lung diseases with minimal systemic exposure.
Investors · 1
Funding
SEC filings, press & company announcements- Undisclosed amountseries BMay 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Splisense do?
- SpliSense develops antisense oligonucleotides (ASOs) — small synthetic RNA-binding molecules — designed using proprietary algorithms for therapeutic applications including splicing modulation and gene silencing. The company focuses on inhaled ASOs delivered directly to the lungs for treating pulmonary and obstructive lung diseases with minimal systemic exposure.
- Who are Splisense's investors?
- Splisense's investors include Israel Biotech Fund.